A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation
Contact:
NCT Number:
Protocol:
AAAU1524
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans.
Are you Eligible? (Inclusion Criteria)
- Are you 18 years or older?
- Do you have locally advanced/unresectable or metastatic solid tumor with documented KRAS G12D mutation?
- Have you never been treated with another specific KRAS G12D inhibitor?
Specialty Area(s)
Bladder Cancer , Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Thyroid Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
